Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.

Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators.

N Engl J Med. 2005 Jan 6;352(1):29-38.

3.

Comparison of statins in hypertriglyceridemia.

Stein EA, Lane M, Laskarzewski P.

Am J Cardiol. 1998 Feb 26;81(4A):66B-69B. Review.

PMID:
9526817
4.

Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol with statins.

Ferrières J.

Am J Cardiovasc Drugs. 2009;9(2):109-15. doi: 10.2165/00129784-200909020-00005. Review.

PMID:
19331439
5.

[LDL cholesterol in normal range. The lower the better? Implications of the GREACE study].

März W.

MMW Fortschr Med. 2003 Dec 11;145(50):46-9. Review. German.

PMID:
14963971
6.

Cholesterol lowering in atherosclerosis.

Brown WV.

Am J Cardiol. 2000 Aug 24;86(4B):29H-32H. Review.

PMID:
11021253
7.

Managing dyslipidemia in the high-risk patient.

Stein EA.

Am J Cardiol. 2002 Mar 7;89(5A):50C-57C. Review.

PMID:
11900720
8.

Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.

Kang S, Liu Y, Liu XB.

Clin Ther. 2013 Aug;35(8):1125-36. doi: 10.1016/j.clinthera.2013.06.006. Epub 2013 Aug 7. Review.

PMID:
23932462
9.

[Indications for statin therapy in patients with acute coronary syndrome of ischemic origin].

Raddino R, Della Pina P, Gorga E, Caretta G, Madureri A, Dei Cas L.

G Ital Cardiol (Rome). 2010 Oct;11(10 Suppl 1):78S-83S. Review. Italian.

PMID:
21416832
10.

Effect of statin therapy on the progression of coronary atherosclerosis.

Tian J, Gu X, Sun Y, Ban X, Xiao Y, Hu S, Yu B.

BMC Cardiovasc Disord. 2012 Sep 1;12:70. doi: 10.1186/1471-2261-12-70. Review.

11.

Lipid-lowering drugs and heart failure: where do we go after the statin trials?

Strandberg TE.

Curr Opin Cardiol. 2010 Jul;25(4):385-93. Review.

PMID:
20549843
12.

Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?

Athyros VG, Tziomalos K, Karagiannis A, Wierzbicki AS, Mikhailidis DP.

Curr Opin Cardiol. 2010 Jul;25(4):406-10. doi: 10.1097/HCO.0b013e3283393c1a. Review.

PMID:
20375883
13.

Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound.

Gao WQ, Feng QZ, Li YF, Li YX, Huang Y, Chen YM, Yang B, Lu CY.

BMC Cardiovasc Disord. 2014 May 2;14:60. doi: 10.1186/1471-2261-14-60. Review.

14.

Reducing morbidity and mortality in high risk patients with statins.

Singh V, Deedwania P.

Vasc Health Risk Manag. 2009;5(2):495-507. Epub 2009 Jun 7. Review.

15.

Statin loading before percutaneous coronary intervention: proposed mechanisms and applications.

Nusca A, Melfi R, Patti G, Sciascio GD.

Future Cardiol. 2010 Sep;6(5):579-89. doi: 10.2217/fca.10.77. Review.

PMID:
20932108
16.

High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.

Koenig W.

Int J Cardiol. 2013 Oct 15;168(6):5126-34. doi: 10.1016/j.ijcard.2013.07.113. Epub 2013 Aug 24. Review.

PMID:
23978367
17.

Role of C-reactive protein when prescribing a statin.

Kinlay S.

Curr Atheroscler Rep. 2012 Feb;14(1):26-32. doi: 10.1007/s11883-011-0218-8. Review.

PMID:
22125118
18.

Lipid management for the prevention of cardiovascular disease.

Schaefer JR.

Curr Pharm Des. 2011;17(9):852-60. Review.

PMID:
21418030
20.

Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?

Ridker PM.

Curr Atheroscler Rep. 2013 Jan;15(1):295. doi: 10.1007/s11883-012-0295-3. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk